Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy?Eli Lilly's new diabetes pill matches Ozempic's effectiveness, with hopes for regulatory approval and a growing obesity treatment market.
New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side EffectsEli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
Eli Lilly Moves First in India, Beats Novo in Obesity Drug ShowdownEli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy? Eli Lilly's new diabetes pill matches Ozempic's effectiveness, with hopes for regulatory approval and a growing obesity treatment market.
New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects Eli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
Eli Lilly Moves First in India, Beats Novo in Obesity Drug Showdown Eli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
Hot Topics